OraSure Technologies, Inc. (NASDAQ:OSUR) EVP Anthony Zezzo II sold 72,916 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $21.26, for a total value of $1,550,194.16. Following the sale, the executive vice president now owns 218,326 shares in the company, valued at $4,641,610.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of OraSure Technologies, Inc. (NASDAQ OSUR) traded up 1.45% during mid-day trading on Friday, hitting $20.26. The stock had a trading volume of 863,698 shares. The stock has a 50 day moving average price of $18.98 and a 200 day moving average price of $14.50. OraSure Technologies, Inc. has a 52 week low of $6.87 and a 52 week high of $21.59. The firm has a market cap of $1.20 billion, a PE ratio of 37.45 and a beta of 1.57.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.07 by $0.02. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The company had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. During the same quarter last year, the company posted $0.07 EPS. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. Equities research analysts expect that OraSure Technologies, Inc. will post $0.48 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Anthony Zezzo II Sells 72,916 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) Stock” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/19/anthony-zezzo-ii-sells-72916-shares-of-orasure-technologies-inc-nasdaqosur-stock-updated.html.

Several institutional investors have recently modified their holdings of OSUR. Suntrust Banks Inc. acquired a new position in shares of OraSure Technologies during the first quarter valued at about $596,000. Bank of New York Mellon Corp raised its position in shares of OraSure Technologies by 107.4% in the first quarter. Bank of New York Mellon Corp now owns 816,172 shares of the medical instruments supplier’s stock valued at $10,553,000 after buying an additional 422,645 shares during the last quarter. Capital Fund Management S.A. acquired a new position in shares of OraSure Technologies during the first quarter valued at about $144,000. State Board of Administration of Florida Retirement System raised its position in shares of OraSure Technologies by 50.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 71,830 shares of the medical instruments supplier’s stock valued at $929,000 after buying an additional 24,072 shares during the last quarter. Finally, 361 Capital LLC acquired a new position in shares of OraSure Technologies during the first quarter valued at about $218,000. Institutional investors own 89.76% of the company’s stock.

A number of analysts have recently issued reports on OSUR shares. Jefferies Group LLC boosted their price objective on OraSure Technologies from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, June 28th. Canaccord Genuity upped their price target on OraSure Technologies from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, June 28th. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Saturday, May 6th. BidaskClub cut OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Finally, Stephens reiterated an “overweight” rating and issued a $19.00 price target (up from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $15.46.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.